Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2100712 | 0.94 | SYK (0.64) | SYKIGF1RROCK2ROCK1RET | |
| SCHEMBL2100717 | 0.92 | SYK (0.66) | SYKIGF1RRETAURKACDC7 | |
| SCHEMBL1973780 | 0.89 | SYK (0.77) | SYKROCK2ROCK1AURKACDC7 | |
| SCHEMBL2103083 | 0.89 | BCL6 (0.65) | SYKIGF1RROCK2ROCK1RET | |
| SCHEMBL657771 | 0.84 | SYK (0.69) | SYKIGF1RROCK2ROCK1RET | |
| SCHEMBL658234 | 0.84 | SYK (0.74) | SYKROCK2ROCK1AURKACDC7 | |
| SCHEMBL2102889 | 0.84 | SYK (0.67) | SYKIGF1RROCK2ROCK1RET | |
| SCHEMBL657477 | 0.81 | SYK (0.67) | SYKIGF1RROCK2ROCK1RET | |
| SCHEMBL2104626 | 0.81 | SYK (0.67) | SYKIGF1RROCK2ROCK1RET | |
| SCHEMBL656434 | 0.81 | SYK (0.73) | SYKIGF1RROCK2ROCK1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120230984-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | claimed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | claimed |
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120230984-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | SYK 2199/4885IGF1R 3818/4885ROCK2 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.